In a relatively short span of time, Aptose (APTO) has gone from a little-known Canadian biotech toiling largely in obscurity to a promising name with wider sell-side coverage. That expanded interest isn’t unreasonable in my view, as promising (but very early) data have made an initial case that Aptose might really have something special with its pan-FLT3/pan-BTK inhibitor CG-806 for hematological cancers.
There remains a long road between commercial success and today, though, and while I do think Aptose has made a strong case for how and why CG-806 is meaningfully better than